Press release from Companies
Publicerat: 2021-02-11 07:45:00
Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 6. April – 31 December 2020. The Year-end report is available as an attached document to this press release and on www.cessatech.com under Investor, ‘Filings & Reports’. The company is on track with Q4 activities and getting ready for an exciting year.
Fourth quarter 2020 (1 October – 31 December):
Highlights during Q4-2020
Finalized a very successful IPO in December with an oversubscription rate of app 680%
"I would like to welcome all new shareholders – and acknowledge you for the strong confidence in our business, our product and us. Together with an extraordinary team, I am looking forward to transforming Cessatech closer to a phase III company - with three (3) major milestones in 2021, the clinical results of 3 studies - 2021 will be a very exciting year" Says Jes Trygved, CEO
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.